Sphere Power Past Earnings Performance
Past criteria checks 0/6
Sphere Power's earnings have been declining at an average annual rate of -39.8%, while the Biotechs industry saw earnings growing at 16.6% annually. Revenues have been growing at an average rate of 26.3% per year.
Key information
-39.8%
Earnings growth rate
-36.7%
EPS growth rate
Biotechs Industry Growth | 11.7% |
Revenue growth rate | 26.3% |
Return on equity | -68.1% |
Net Margin | -63.9% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Sphere Power (KOSDAQ:203690) Is Carrying A Fair Bit Of Debt
Jul 31Lacklustre Performance Is Driving Sphere Power Inc.'s (KOSDAQ:203690) 25% Price Drop
Jun 20Investors Don't See Light At End Of Sphere Power Inc.'s (KOSDAQ:203690) Tunnel And Push Stock Down 29%
May 06Further Upside For Sphere Power Inc. (KOSDAQ:203690) Shares Could Introduce Price Risks After 44% Bounce
Mar 21Sphere Power Inc. (KOSDAQ:203690) Soars 44% But It's A Story Of Risk Vs Reward
Mar 21Would Prostemics (KOSDAQ:203690) Be Better Off With Less Debt?
Apr 13What Type Of Returns Would Prostemics'(KOSDAQ:203690) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Feb 17Do Institutions Own Prostemics Co., Ltd. (KOSDAQ:203690) Shares?
Dec 22Revenue & Expenses Breakdown
How Sphere Power makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 32,993 | -21,079 | 5,030 | 7 |
31 Mar 24 | 35,179 | -24,450 | 5,111 | 40 |
31 Dec 23 | 37,253 | -24,368 | 4,397 | 116 |
30 Sep 23 | 36,810 | -14,050 | 4,409 | 162 |
30 Jun 23 | 33,201 | -7,282 | 5,440 | 83 |
31 Mar 23 | 29,441 | -5,794 | 5,837 | 694 |
31 Dec 22 | 26,576 | -5,367 | 5,736 | 1,224 |
30 Sep 22 | 27,094 | -7,523 | 6,232 | 1,769 |
30 Jun 22 | 29,975 | -11,923 | 6,652 | 2,280 |
31 Mar 22 | 32,156 | -10,943 | 7,217 | 1,793 |
31 Dec 21 | 32,529 | -7,242 | 7,755 | 1,215 |
30 Sep 21 | 34,015 | -5,696 | 7,917 | 792 |
30 Jun 21 | 32,540 | -6,030 | 7,211 | 466 |
31 Mar 21 | 25,702 | -5,520 | 6,112 | 364 |
31 Dec 20 | 18,031 | -7,293 | 5,485 | 370 |
30 Sep 20 | 13,225 | -1,708 | 4,901 | 352 |
30 Jun 20 | 8,321 | -1,636 | 4,700 | 318 |
31 Mar 20 | 8,053 | -1,630 | 4,750 | 335 |
31 Dec 19 | 7,127 | -3,183 | 4,864 | 370 |
30 Sep 19 | 6,611 | -4,136 | 4,710 | 387 |
30 Jun 19 | 5,493 | -5,496 | 4,677 | 413 |
31 Mar 19 | 4,890 | -6,654 | 4,801 | 433 |
31 Dec 18 | 4,720 | -6,299 | 4,803 | 423 |
30 Sep 18 | 4,866 | -4,696 | 5,291 | 406 |
30 Jun 18 | 4,940 | -4,395 | 5,803 | 366 |
31 Mar 18 | 5,946 | -2,696 | 6,261 | 375 |
31 Dec 17 | 6,565 | -3,158 | 6,534 | 392 |
30 Sep 17 | 8,154 | -998 | 6,684 | 439 |
30 Jun 17 | 10,998 | 1,324 | 6,400 | 453 |
31 Mar 17 | 12,798 | 2,686 | 6,282 | 468 |
31 Dec 16 | 14,164 | 4,313 | 5,941 | 464 |
30 Sep 16 | 15,920 | 5,627 | 5,854 | 279 |
30 Jun 16 | 15,126 | -8,567 | 5,794 | 217 |
31 Mar 16 | 14,671 | -8,717 | 5,646 | 117 |
31 Dec 15 | 14,835 | -8,517 | 5,400 | 57 |
31 Dec 13 | 10,058 | 2,380 | 4,133 | 43 |
Quality Earnings: A203690 is currently unprofitable.
Growing Profit Margin: A203690 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A203690 is unprofitable, and losses have increased over the past 5 years at a rate of 39.8% per year.
Accelerating Growth: Unable to compare A203690's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A203690 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (41.1%).
Return on Equity
High ROE: A203690 has a negative Return on Equity (-68.14%), as it is currently unprofitable.